# Tetanus and Diphtheria Combined Vaccine (Td)

**Date No Longer Available:** June 30, 2022

**Rationale for Update:**
- dTap replacing Td for routine Adult immunization.

Please consult the Product Monograph[^1] for further information about the product.

<table>
<thead>
<tr>
<th>Td ADSORBED</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturer</strong></td>
</tr>
<tr>
<td><strong>Licensed use</strong></td>
</tr>
<tr>
<td><strong>Off-license use</strong></td>
</tr>
</tbody>
</table>
| **Indications for use of provincially funded vaccine** | - Primary or reinforcing immunization of individuals 18 years of age and older.  
- Individuals who sustain a wound injury need to have their tetanus immunization history assessed. See [Tetanus Post-exposure Prophylaxis in Injury/Wound Management](#). |
| **Notes:** | - Td may be administered as an alternative to dTap OR when dTap is not available OR the pertussis component is contraindicated.  
- Adult recipients of hematopoietic stem cell transplantation (HSCT). See [Immunization for Adult Hematopoietic Stem Cell Transplant](#) and [Biological Products - DTaP-IPV Hib](#). |
| **Dose** | 0.5 mL |
| **Route** | Intramuscular |
| **Schedule** | **Primary vaccine series:**  
- Dose 1: day 0  
- Dose 2: 4 – 8 weeks after dose 1  
- Dose 3: 6 – 12 months after dose 2  
Reinforcing doses are recommended at 10-year intervals.  
See [Adults: Immunization Schedule](#). |
| **Note:** | - dTap is used for routine adult immunization. |
| **Contraindications** | - Known severe hypersensitivity to any component of Td Adsorbed.  
- Anaphylactic or other allergic reaction to a previous dose of vaccine containing tetanus or diphtheria antigens. |

[^1]: [Product Monograph](#)
### Precautions

- Frequent booster doses of tetanus and diphtheria toxoids may lead to severe local and systemic reactions and may be associated with high levels of circulating antitoxin. See [Interpretation of Diphtheria Antitoxin Levels (DAT) and Tetanus Antitoxin Levels (TAT)].
- If Guillain-Barré Syndrome (GBS) occurred within six weeks of immunization with a previous dose of vaccine containing tetanus toxoid, it is prudent to withhold subsequent doses of tetanus-containing vaccine. Those who develop GBS outside this interval may receive subsequent doses of tetanus toxoid-containing vaccine. If there is a history of both *Campylobacter* infection and receipt of a tetanus-containing vaccine within six weeks before the onset of GBS, consultation with an infectious disease specialist is advised.

### Possible reactions

See Product Monograph.

### Pregnancy

Susceptible pregnant women may receive Td vaccine if indicated. There is no evidence to suggest a risk to the fetus or to the pregnancy from maternal immunization with Td.

### Lactation

May be administered safely to breastfeeding mothers if indicated.

### Program Notes

- 1980 July 9 – Introduced into program.
- 2021 January 1 – dTap replacing Td for routine Adult immunization.
- 2022 June 30 – Td vaccine no longer available.

#### Historical notes:

- 1930– Diphtheria toxoid became available.
- 1930-1994 August 1 – Diphtheria toxoid became available.
- 2004 September 1 - dTap - Introduced into program.
- 2015 February 11 – TdP introduced into program.

### References